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Résumé 
Introduction: Plusieurs patients atteints d’un cancer de la prostate (CaP) se 
verront prescrire l'hormonothérapie (HT) en raison du stade avancé ou en cas 
d’une récidive de la maladie, pour freiner la progression de la maladie et améliorer 
leur survie.  Cependant, l’HT présente des effets pouvant nuire significativement à 
la santé du patient. 
 
Objectif : Cerner l'impact de l’HT sur l’apparition de complications squelettiques et 
non-squelettiques. 
 
Méthodes : Nous avons identifié 15 842 québécois atteints du CaP.  Nous avons 
quantifié les complications squelettiques et non-squelettiques. Les effets de l’HT 
ont été quantifiés à l'aide de modèles statistiques de régression tenant compte des 
risques compétitifs, tels que les comorbidités pré-existantes ou la mort prématurée. 
 
Résultats : À 8 ans, l’incidence d’ostéoporose est de 4.4% chez les hommes sans 
HT, 10.8% chez ceux avec HT≤1.8 ans, 19.7% HT>1.8 ans et 11.4% pour les 
orchiectomisés. Pour la même durée, l’incidence de fracture vertébrale est de 
1.9%, 7.5%, 7.5% et 8.1% pour les même groupes. Pour la fracture de hanche les 
taux sont de 1.9%, 6.4%, 8.0% et 9.3%, respectivement. Dans les modèles 
mutlivariés, l’HT >1.8 ans et l’orchiectomie augmentent significativement le risque 
d’évènements squelettiques. Une exposition prolongée à l’HT et l’orchiectomie 
augmentent le risque de détérioration cognitive. Finalement, l’HT prolongée 
augmente significativement le risque de maladies vasculaires périphériques et 
cérébrovasculaires. 
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Conclusions : L’hormonothérapie prolongée et l’orchiectomie augmentent 
significativement le risque de complications squelettiques chez les hommes 
québécois. Nos données confirment également l’effet de l’hormonothérapie sur le 
risque cardiovasculaire et sur la détérioration de la fonction cognitive. 
 
Mots-clés : cancer, prostate, hormonothérapie, fracture osseuse, ostéoporose, 
démence, maladies vasculaires 
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Abstract 
Purpose: In men with prostate cancer (PCa) androgen deprivation therapy (ADT) 
predisposes to skeletal-related events (SREs) defined as osteoporosis or bone 
fractures and non-skeletal-related (NSREs) events, such as diabetes mellitus and 
myocardial infarction. We tested whether this effect is also detectable within a large 
Canadian cohort. 
 
Material and Methods: Within the Quebec Health Plan database we identified 
15 842 men diagnosed with PCa who were treated between 1992 and 2000 with 
either luteinizing hormone-releasing hormone agonists [LHRHa] or orchiectomy. 
Separate competing-risks regression models tested the effect of orchiectomy vs. 
LHRHa vs. no ADT on the incident rate of three SREs and twelve NSREs. 
 
Results: At 8 years, the incidence rates of osteoporosis were 4.4% in patients 
unexposed to ADT, 10.8% in LHRHa ≤1.8 years, 19.7% in LHRHa >1.8 years and 
11.4% in orchiectomized patients. Similarly, the rates of spinal fracture were 1,9%, 
7.5%, 7.25% and 8.1% for the same groups. Finally, the rates of hip fracture were 
respectively 1.9%, 6.4%, 8.0% and 9.3%. In multivariable competing-risks 
analyses, exposure to LHRHa >1.8 years and orchiectomy significantly increased 
all three SREs. Conversely, the independent predictor status was not confirmed for 
patients exposed to LHRHa ≤1.8 years. Moreover, prolonged LHRHa therapy 
increases the incidence rates of three NSREs, namely, dementia, peripheral and 
cerebrovascular disease (all, p≤0.02). Orchiectomy only increases the rate of 
dementia. 
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Conclusions: Exposure to prolonged LHRHa therapy or orchiectomy significantly 
increases the risk of SREs in Canadian men. Our results also confirm the effect of 
ADT on cardiovascular risks and cognitive function. 
 
Keywords : prostate cancer, androgen deprivation therapy, skeletal fractures, 
metabolic complications 
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 Introduction 
According to Statistics Canada, in 2011, prostate cancer (PCa) represented 
the most common cancer diagnosed in men (27.5% of new cancer cases, Fig. 1) 
and raked third in terms of mortality, after lung and colon cancers.1 
 
Figure 1. Percentage Distribution of Estimated New Cases and Deaths for Selected 
Cancers, Males, Canada, 2011.1 
 
In Canada, 25 500 new cases were expected in 2011. In Quebec, at least 
5100 new PCa cases were estimated. The natural history of PCa is more 
protracted that than for most other solid tumors. Its treated natural history usually 
spans between one or two decades, exposing cancer survivors to long period of 
treatments and their potential side effects. 
 
Currently, PCa his staged both clinically and pathologically with the TNM 
(Tumor, Node, Metastasis) staging system (Table 1). Regular updated of this 
system are made to improve the classification and categorization of the patients, 
for clinical and research purpose. The most update system was published in 2010 
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by the American Joint Committee on Cancer (AJCC), in the AJCC Cancer Staging 
Manual, Seventh Edition, by Springer.  
 
Table 1. TNM staging system for prostate cancer. 
 
 
 
In it’s locally and advanced stage, the treatment of PCa requires the use of 
androgen deprivation therapy (ADT). The rationale of ADT in the field of PCa 
stems from the observations of a Canadian scientist Charles Huggins (Nobel Prize 
laureate 1966), who demonstrated that the male hormone testosterone is 
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necessary to stimulate PCa growth and its progression.2 The latter resulted in the 
use of ADT, initially in the form of surgical castration (bilateral orchiectomy) and 
later in the form of chemical castration (luteinizing hormone-releasing hormone 
agonists [LHRHa]), as the mainstay therapy for locally advanced or metastatic 
PCa. The beneficial effects of ADT in men with locally advanced or metastatic PCa 
consist of delayed disease progression and palliation of disease symptoms.3, 4 
Approximately one third of all the newly diagnosed PCa cases are too advanced 
locally to benefit from definitive therapy or show frank evidence of metastatic 
disease.5 Additionally, ADT represents a well-recognized and widely used form of 
therapy for localized PCa, especially in individuals with restricted life expectancy 
due to important comorbidities. Some 10% of newly diagnosed PCa cases fulfill the 
characteristics of this category of individuals.  
 
Recently, a second formal indication for ADT was coined, when ADT 
efficacy was confirmed in the setting of localized PCa. Specifically, its co-
administration with radiation therapy improved survival in men with unfavourable 
disease features.6-9 Approximately, 25% of patients with newly diagnosed localized 
PCa harbour unfavourable PCa characteristics and receive ADT in adjuvant setting 
for between 3 and 24 months.10 The third indication for ADT applies to patients that 
demonstrate disease relapse (commonly elevated and rising serum prostate-
specific antigen [PSA]) after either radical prostatectomy or external beam 
radiotherapy for initially localized disease.11 Five years after radical prostatectomy 
or radiotherapy, at least 30% of men fall into this category. Taken together, at least 
one in two individuals diagnosed with PCa will temporarily (in adjuvant setting) or 
permanently exposed to ADT. This implies that annually at least 12 750 men will 
receive ADT throughout Canada. Of these, more than 2500 individuals will be 
treated with ADT in the province of Quebec. In consequence, a large proportion of 
men may be exposed to ADT. 
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Hormonal therapy is usually administered for several years and not 
infrequently for decades. Therefore, the burden related to the use of ADT is not 
only significant epidemiologically, but has important clinical (potential side-effects) 
and health economics (cost of ADT: average 4500 $ / patient / syear) 
implications.12 The cost of ADT may actually be higher due to its side effects. 
Recently, the medical literature reported an exponential rise in the type and rates 
of such complications. Androgen deprivation therapy for PCa in the form of 
orchiectomy, luteinizing hormone-releasing hormone agonists (LHRHa) and/or 
antiandrogens has been associated with several side effects (Fig. 2).13 Beside the 
well-established side effects (loss of libido, erectile dysfunction, fatigue, hot 
flashes, altered body composition, etc.), recent report linked ADT to a broader 
range of adverse outcomes.3, 13, 14 These consist of skeletal complications 
(osteopenia, osteoporosis and skeletal fractures), as well as of metabolic changes 
(hyperglycemia and insulin resistance, frank diabetes mellitus, hypertension, 
atherosclerosis, cardiovascular disease and cognitive decline).15-22 Moreover, ADT-
related side effects may undermine patient’s quality-of-life and may predispose to 
lower life expectancy.23-25 Even more worrisome, ADT has been associated with 
increased cardiovascular morbidity and mortality. To date, no study addressed the 
rate of skeletal and metabolic (non-skeletal) complications in a Canadian 
population. Currently, virtually exclusively data from the United States are used to 
substantiate the association between ADT and various skeletal and metabolic 
detriments. 
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Figure 2. Side effects of androgen deprivation therapy.13 
 
The link between ADT and fractures was addressed in one large-scale 
population-based analysis of the Surveillance, Epidemiology and End Results 
(SEER) database after linkage with Medicare records and restricted to United 
States male 65 years old or older (n= 50000).15 It demonstrated a 7% absolute 
increase in bone fractures in PCa patients exposed to ADT. Unfortunately, no other 
contemporary, large-scale, population-based studies validated the effect of ADT on 
fracture risk or other, non-skeletal morbidities that may potentially stem from ADT. 
Of studies that addressed skeletal ADT morbidities, virtually all relied form the 
United States. Therefore, there is need for large-scale, population-based 
assessment of the association between ADT and fracture risk, to corroborate or 
refute that the suggested 7% absolute risk in skeletal complications, is of same 
magnitude in Canadian men.  
 
An even grater greater paucity of data applies to several other potential ADT 
side effects. For example, the association between ADT and various 
manifestations of the metabolic syndrome were studied in only 40 patients from the 
United States and these data were used to propose a causal effect.26 Based on 
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these sample and generalizability limitations, it is possible that other variables 
predispose men from the United States to many putative side effects of ADT.  
 
Clinical observations, suggest that the rates in Quebec men might not be as 
elevated, as is reported in predominantly literature from the United States (for 
example, virtually complete absence of clinically meaningful fracture). Under this 
premise, several of preventive measures (bone density scans, diabetes screening, 
etc.) might be unnecessary. However, no reports provide factual complication 
rates. Based on these observations, we hypothesized that the rates of skeletal and 
non-skeletal side effects that are associated with ADT are not significantly higher in 
ADT-exposed individuals than in ADT-unexposed PCa controls. Differences in 
genetic, environmental, life style and dietary risk factors that distinguish Quebec 
men from their United States counterparts may account for these clinical 
observations.27, 28 For example, fat-rich diet and higher rate of obesity, as know to 
affect many men from the US, may predispose to higher rates of bone loss.29, 30 
Therefore, studies from the US may exaggerate the detrimental effect of ADT on 
SREs. Specifically, we examined the rate of skeletal and metabolic events in 
patients exposed to ADT administered in the context of PCa and compared these 
rates to those recorded in men treated with definitive therapy (radiation or radical 
prostatectomy) without any ADT exposure. The practical and clinical implications of 
our findings may result in more specific and more selective use of ADT. This may 
in turn prevent side effects and save cost. 
 
  
Material and Methods  
The Quebec Health Plan represents the exclusive insurer in the Province of 
Quebec. Its database allows ascertainment of all health services covered by the 
Plan. These include ADT (LHRHa or bilateral orchiectomy) for patients diagnosed 
with PCa. The Health Plan database is used for reimbursement purposes and 
analyses of health services utilization. The Health Plan relies on the 9th version of 
the International Classification of Diseases (ICD-9) diagnostic codes and their 
respective dates. The Health Plan allowed us to retrieve the date of the initial 
diagnosis of each of the specific morbidities, namely, skeletal morbidities: 
osteoporosis (ICD-9 733.0), hip fracture (ICD-9 820) and spinal fracture (ICD-9 
805) and non-skeletal morbidities: myocardial infarction (ICD-9 410, 411), 
congestive heart failure (ICD-9 398, 402, 428), peripheral vascular disease (ICD-9 
440-447), dementia (ICD-9 290, 291, 294), cerebrovascular disease (ICD-9 430-
433, 435), chronic pulmonary disease (ICD-9 491-493), connective tissue disease 
(ICD-9 710, 714, 725), ulcer disease (ICD-9 531-534), moderate to severe renal 
disease (ICD-9 403, 404, 580-586), diabetes (ICD-9 250), mild liver disease (ICD-9 
571, 573), and moderate to severe liver disease (ICD-9 070, 570, 572). 
 
The database provides diagnostic codes from as early on as January 1st, 
1983. Follow-up information was available until July 1st, 2004. Based on stage 
migration, which occurred in the PSA-era, only prostate cancer cases treated after 
January 1st, 1992 were included. Patients diagnosed and treated after December 
31st, 2000 were excluded based on length of follow-up considerations.  
 
To assess the effect of ADT on the incidence rate of the three SREs and 
twelve NSREs, we queried the database for PCa patients treated with LHRHa or 
bilateral orchiectomy, who did not undergo any form of definitive therapy, such as 
radical prostatectomy (RP) or external beam radiotherapy (XRT). We also queried 
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for patients treated with RP and/or XRT, who were not exposed to any form of 
ADT. This group represented the controls. 
 
Due to the use of reimbursement records, the database allowed exact 
ascertainment of LHRHa exposure, orchiectomy, RP, and definitive XRT. For 
orchiectomy patients, the starting point of follow-up was defined at the date of 
bilateral orchiectomy. For LHRHa patients, only those who filled their prescription 
more than 90% of the time were considered. LHRHa patients were divided 
according to the median duration of LHRHa exposure (LHRHa ≤1.8 years and 
LHRHa >1.8 years). For RP and XRT patients (controls), the starting point of 
follow-up was defined at RP or first XRT session. 
 
We examined fifteen separate endpoints. Each endpoint consisted of a new 
diagnosis of any SREs or NSREs. Each event was assessed in separate 
univariable and multivariable competing-risks regression models. The analyses 
tested the effect of ADT exposure (LHRHa ≤1.8 years vs. LHRHa >1.8 years vs. 
orchiectomy vs. no ADT) on these endpoints. All analyses accounted for other-
cause mortality, as described by Fine and Gray.31 First, the incidence rates at 1, 5 
and 8 years of follow-up were defined using cumulative incidence analyses that 
account for other-cause mortality. Subsequently, we relied on multivariable 
competing-risks regression models to account for the effect of other variables. 
 
Age differences may confound more the relationship between ADT exposure 
and the diagnosis of SREs or NSREs. We adjusted the confounding effect of age 
in all multivariable competing-risks regression models. Moreover, the effect of 
socioeconomic status was adjusted for using the postal code and the geographic 
region of residence. We also adjusted for the year of treatment, since temporal 
trends may affect the rate of ADT associated morbidities. Finally, since other pre-
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existing health conditions may predispose to additional health problems, we also 
adjusted for any morbidity (concomitant SRE or NSRE) that was diagnosed either 
before or after the beginning of follow-up. In multivariable competing-risks 
regression models, the dates of diagnoses of any pre-morbid conditions, if 
applicable, was coded as time-dependent covariates  
 
All statistical tests were performed using S-Plus Professional, version 1.0 
(MathSoft Inc., Seattle, Washington). Moreover, all tests were two-sided with a 
significance level set at 0.05. 
  
Results 
The descriptives of the 15842 assessable patients are shown in Table 2. 
The median age of the patients treated with LHRHa ≤1.8 years, LHRHa >1.8 years 
and orchiectomy was 7.7 to 9.4 years higher than that of their counterparts not 
treated with any form of ADT. The underlying comorbidities at the start of follow-up 
did not differ between the four groups. The effect of these and other potential 
differences were addressed in multivariable analyses. 
 
Table 2. Descriptive characteristics of the study population (n=15842). 
 
Legend 
LHRHa: Luteinizing hormone-releasing hormone agonists 
ADT: androgen deprivation therapy 
 
 Overall 
population 
Patients unexposed 
to ADT 
Patients exposed 
to LHRHa 
for ≤1.8 years 
Patients exposed 
to LHRHa 
For>1.8 years 
Patients treated with 
orchiectomy 
Number of patients 15842 (100%) 10072 (63.6%) 2037 (12.9%) 1877 (11.8%) 1856 (11.7%) 
Age (years) 
Mean (median) 
Range 
 
69.1 (68.7) 
29.5-100.9 
 
66.5 (66.3) 
41.2-92.86 
 
75.2 (75.4) 
39.9-100.9 
 
75.0 (75.7) 
46.9-96.0 
 
70.2 (74.0) 
29.5-96.5 
Charlson Comorbidity Index at 
the start of follow-up 
Mean (median) 
Range 
 
 
2.1 (2.0) 
0-13 
 
 
2.0 (2.0) 
0-12 
 
 
2.3 (2.0) 
0-13 
 
 
2.1 (2.0) 
0-10 
 
 
2.2 (2.0) 
0-12 
Antiandrogen therapy use 3385 0 1686 (82.8) 1699 (90.5) 0 
Prevalence of morbidities 
Myocardial infarction 
Congestive heart failure 
Peripheral vascular disease 
Dementia 
Cerebrovascular disease 
Chronic pulmonary disease 
Connective tissue disease 
Ulcer disease 
Moderate to severe renal 
disease 
Diabetes Mellitus 
Mild liver disease 
Moderate to severe liver disease 
 
3628 (22.9) 
3226 (21.6) 
4074 (25.7) 
1319 (8.4) 
2039 (12.9) 
4749 (29.9) 
1048 (6.6) 
2551 (16.1) 
1926 (12.2) 
4014 (25.3) 
831 (5.3) 
206 (1.3) 
 
2979 (20.7) 
1725 (17.2) 
2431 (24.2) 
541 (5.4) 
1176 (11.7) 
2960 (29.4) 
659 (6.5) 
1642 (16.3) 
983 (9.7) 
2506 (24.9) 
561 (5.6) 
145 (1.5) 
 
556 (27.3) 
601 (29.5) 
599 (29.4) 
266 (12.0) 
303 (14.9) 
637 (31.3) 
131 (6.4) 
327 (16.1) 
326 (16.0) 
494 (24.3) 
102 (5.0) 
28 (1.4) 
 
529 (28.2) 
574 (30.6) 
557 (29.7) 
231 (12.3) 
309 (16.5) 
576 (30.7) 
152 (8.1) 
288 (15.4) 
310 (16.5) 
565 (30.1) 
66 (3.6) 
13 (0.7) 
 
464 (25.0) 
526 (28.4) 
487 (26.2) 
281 (15.2) 
251 (13.5) 
576 (31.0) 
106 (5.7) 
294 (15.9) 
307 (16.5) 
449 (24.2) 
102 (5.5) 
20 (1.1) 
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Figure 3 shows ADT use and type through the study period. From 1992 to 
2000, almost half of patients received a form of ADT. Orchiectomy use declined 
significantly during this period of time, mostly due to introduction of chemical 
castration since 1995. For example in 1992, 39.7% were treated with orchiectomy, 
but in year 2000 only 6.3%. 
 
 
Figure 3. The type of androgen deprivation therapy used during the study period 
(1992-2000).  
 
Legend 
ADT: androgen deprivation therapy 
LHRH: luteinizing hormone-releasing hormone agonists 
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Skeletal-Related Events: 
Table 3 shows incidence rates of newly diagnosed osteoporosis, hip fracture 
and spinal fracture that were obtained from cumulative incidence models that 
account for the effect of other-cause mortality. For example at 8 years of follow-up, 
the incident rate of osteoporosis was 10.8% (95% confidence interval [CI] 8.4-13.9) 
in patients treated with LHRHa ≤1.8 years, 19.7% (95%CI 17.0-22.8) for those 
treated with LHRHa >1.8 years and 11.4% (95%CI 9.3-13.9) in patients treated 
with orchiectomy vs. 4.4% (95%CI 3.8-5.0) in patients unexposed to any form of 
ADT. For the same time-points and for the same patients groups, incident rates of 
spinal fracture were 7.5% (95%CI 5.6-8.2), 7.5% (4.9-8.3), 8.1% (95%CI 6.5-8.8) 
and 1.9% (95%CI 1.1-2.3). Similarly, the corresponding incident rates of hip 
fractures were 6.4% (95%CI 4.7-7.8), 8.0% (95%CI 5.3-9.9), 9.3% (95%CI 6.7-
11.1) and 1.9% (95%CI 2.2-4.7) for the same four groups of patients.  
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Table 3. Cumulative incidence rates for skeletal-related events defined as osteoporosis, 
spinal fracture or hip fracture, according to type and duration of ADT (orchiectomy vs. 
LHRHa for ≤1.8 years vs. LHRHa for ≤1.8 years). The incidence rates account for other-
cause mortality. 
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The results of the multivariable competing-risks regression models are 
shown in Table 4. In addition to adjustment for other-cause mortality, competing-
risks regression models controlled for the potential confounding effect of other 
covariates. In models that targeted the incident rate of osteoporosis, exposure to 
LHRHa >1.8 years (HR: 2.3; p<0.001) and exposure to orchiectomy (HR: 2.3; 
p<0.001) reached independent predictor status. In models that targeted spinal 
fracture rate, exposure to LHRHa >1.8 years (HR: 1.9; p=0.018) and exposure to 
orchiectomy (HR: 2.2; p<0.001) reached independent predictor status.  Finally, 
when hip fracture was assessed exposure to LHRHa >1.8 years (HR: 1.7; p=0.04) 
and exposure to orchiectomy (HR: 2.2; p<0.001) reached independent predictors 
status. 
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Table 4. Multivariable competing-risks regression models testing the effect of LHRHa or 
orchiectomy vs. no ADT on three separate endpoints: osteoporosis, spinal fractures 
and hip fractures. Each endpoint was analyzed in a separate model. Moreover, LHRHa 
exposure was tabulated between ≤1.8 years (median) and >1.8 years.  The covariates 
consisted of patient age, anti-androgen exposure, postal code, region of residence, 
year of treatment, as well as of twelve non-skeletal morbidities that comprise the 
Charlson comorbidity index. Each of the Charlson comorbidities was coded as a time 
dependent covariate. 
 
SREs Osteoporosis 
Spinal 
fracture 
Hip fracture 
ADT exposure HR; p-value HR; p-value HR; p-value 
Patients exposed to LHRHa for ≤1.8 
years 
1.1; 0.8 1.6; 0.06 1.3; 0.3 
Patients exposed to LHRHa for>1.8 years 2.3; <0.001* 1.9; 0.018* 1.7; 0.04* 
Orchiectomy 2.3; <0.001* 2.2; <0.001* 2.2; <0.001* 
Legend 
ADT: androgen deprivation therapy 
SREs: skeletal-related events 
LHRHa: luteinizing hormone-releasing hormone agonists 
HR: Hazard ratio 
*: Statistically significant  
 
 
Non-Skeletal-Related Events: 
Table 5 shows incidence rates of newly diagnosed twelve NSREs that were 
obtained from cumulative incidence models that account for the effect of other-
cause mortality. For example at 8 years of follow-up, the incident rate of dementia 
was 8.5% (95% confidence interval [CI] 5.9-11.2) in patients treated with LHRHa 
≤1.8 years, 11.3% (95%CI 8.2-14.4) for those treated with LHRHa >1.8 years and 
10.2% (95%CI 8.3-12.1) in patients treated with orchiectomy vs. 3.8% (95%CI 3.2-
4.3) in patients unexposed to any form of ADT. For the same time-points and for 
the same patients groups, incident rates of cerebrovascular disease were 4.8% 
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(95%CI 3.0-6.6), 7.6% (5.3-10.0), 4.4% (95%CI 3.1-5.7) and 6.2% (95%CI 5.5-6.8). 
Similarly, the corresponding incident rates of peripheral vascular disease were 
10.5% (95%CI 6.8-14.1), 13.9% (95%CI 9.9-15.0), 8.8% (95%CI 6.9-10.7) and 
8.4% (95%CI 7.6-10.3) for the same four groups of patients. For the remaining, 
NSREs reported on table 4, cumulative incidences throughout the study period 
were similar between the 4 patients groups. 
 
Table 5. Cumulative incidence rates for twelve non-skeletal-related events according to type 
and duration of ADT (orchiectomy vs. LHRHa for ≤1.8 years vs. LHRHa for ≤1.8 years). 
The incidence rates account for other-cause mortality. 
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The results of the multivariable competing-risks regression models are 
shown in Table 6. In models that targeted the incident rate of dementia, exposure 
to LHRHa >1.8 years (HR: 1.7; p=0.006) and exposure to orchiectomy (HR: 1.7; 
p≤0.001) reached independent predictor status. In models that targeted 
cerebrovascular disease rate, exposure to LHRHa for >1.8 years reached 
independent predictor status (HR: 1.6; p=0.02).  Finally, when peripheral disease 
was assessed, exposure to LHRHa for >1.8 years reached independent predictors 
status (HR: 1.5; p=0.02). 
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Table 6. Multivariable competing-risks regression models testing the effect of LHRHa or 
orchiectomy vs. no ADT on twelve NSREs. Each endpoint was analyzed in a separate 
model. Moreover, LHRHa exposure was tabulated between ≤1.8 years (median) and >1.8 
years.  The covariates consisted of patient age, anti-androgen exposure, postal code, 
region of residence, year of treatment and other comorbidities. Each comorbidity was 
coded as a time dependent covariate. 
 
NSREs 
Myocardial 
infarction 
Congestive 
heart 
failure 
Dementia 
Cerebro-
vascular 
disease  
Chronic 
pulmonary 
disease  
Ulcer 
disease  
Diabetes 
mellitus  
Mild 
Liver 
disease  
Peripheral 
vascular 
disease  
Moderate 
to severe 
Liver 
disease  
Connective 
tissue 
disease 
Moderate 
to severe 
renal 
disease 
ADT 
exposure 
HR; p-
value 
HR; p-
value 
HR; p-value 
HR; p-
value 
HR; p-
value 
HR; p-
value 
HR; p-
value 
HR; p-
value 
HR; p-
value 
HR; p-
value 
HR; p-
value 
HR; p-
value 
LHRHa for 
≤1.8 years 
1.1; 0.7 1.1; 0.9 1.4; 0.06 1.5; 0.05 0.9; 0.3 1.1; 0.5 0.8; 0.5 0.9; 0.1 1.4; 0.07 1.0; 0.3 0.9; 0.2 1.2; 0.3 
LHRHa for 
r>1.8 years 
1.2; 0.5 1.5; 0.06 1.7; 0.006* 1.6; 0.02* 1.1; 0.1 1.1; 0.6 1.1; 0.3 
0.75; 
0.08 
1.5; 0.02* 0.9; 0.6 0.8; 0.5 1.4; 0.06 
Orchiectomy 1.1; 0.2 1.1; 0.3 1.7;<0.001* 0.9; 0.3 1.03; 0.8 0.8; 0.3 0.9; 0.3 1.02; 0.9 0.9; 0.2 0.9; 0.9 0.8; 0.3 1.06; 0.6 
Legend 
ADT: androgen deprivation therapy 
NSREs: non-skeletal-related events 
LHRHa: luteinizing hormone-releasing hormone agonists 
HR: Hazard ratio 
*: Statistically significant  
 
  
Discussion 
Prostate cancer (PCa) is the most commonly male malignancy and is the 
second leading cause of cancer related death in North American men. However, 
rates of non-cancer deaths in men with prostate cancer are greater than in the 
general population and ADT treatment may, in part, be responsible for this 
increase.32 Moreover, a recent communication found that long-term LHRHa 
exposure was associated with greater non-cancer mortality than short-term LHRHa 
therapy.33 Furthermore, Keating et al. recently demonstrated that ADT increases 
the risk of incident diabetes, coronary heart disease, acute myocardial infarction, 
and sudden cardiac death.18 Moreover, several studies have demonstrated the 
deleterious effect of hormonal suppression on bone-health.34, 35 36 37 Virtually all 
large studies that addressed this topic were performed in the United States of 
America, where genetic, environmental and dietary risk factors may substantially 
differ from other part of the world. For example, obesity and PCa may exert a 
synergic effect on the rate of SREs.38, 39 Since obesity rate is higher in the US than 
in Europe or Canada, SREs may be more frequent in the US.40 Finally, recent 
studies highlighted the increasing trend in ADT prescriptions for localized PCa, 
even in absence of any evidence-based benefit.41 Based on these observations, 
we tested the hypothesis that ADT may increase the risk of developing new non-
cancer morbidities in a large population based cohort of patients treated for PCa 
with or without ADT. We tested this hypothesis by quantifying the rate of these 
established SREs and NSREs in Canadian men. 
 
Our results indicated that LHRHa exposure in excess of the median duration 
(1.8 years) significantly predisposes to higher rates of SREs. At 8 years of follow-
up, men exposed to LHRHa duration >1.8 years demonstrated a near 4-fold higher 
rate of SREs relative to men unexposed to ADT. Similarly, we found a near 2-fold 
increase in SREs rates in men exposed to orchiectomy. Interestingly, highest 
incident rates of SREs were recorded men treated with orchiectomy and those 
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exposed to LHRHa >1.8 years. Conversely, the SREs recorded in patients 
exposed with LHRHa ≤ 1.8 years (median) failed to demonstrate statistically 
significant differences from those recorded in patients unexposed to ADT. Taken 
together, our findings imply that LHRHa duration >1.8 years and orchiectomy 
treatment had the most detrimental effects on SREs rates. 
 
In the analyses of spinal and hip fracture rates, orchiectomy was either more 
or equally detrimental to LHRHa exposure duration >1.8 years. Conversely, ADT 
exposure of ≤1.8 years duration was invariably less detrimental than >1.8 years of 
exposure or orchiectomy treatment. This observation is important from a clinical 
perspective as it suggests that intermittent ADT might be less deleterious than 
continuous ADT. Although this hypothesis is attractive it remains to be proven in 
randomized clinical trials. 
 
Our results also show that for most of the NSREs, no significant differences 
in incidences rates were recorded after 8 years of follow up between men exposed 
compared to those unexposed to any type of ADT. This questions the detrimental 
effect of ADT on several metabolic morbidities, such as cardiovascular disease and 
diabetes mellitus. However, our data showed that patients exposed to LHRH for 
more than 1.8 years had near 2-fold higher risk of for peripheral and 
cerebrovascular disease then those unexposed. Multivariable models targeting the 
effect of ADT on vascular disease also confirm the detrimental effect of ADT on the 
vascular health of men exposed to ADT. Moreover, our results also confirmed the 
effect of ADT on cognitive decline, where men exposed to both prolong LHRH 
exposure and orchiectomy had more than 2-fold higher rates of dementia then men 
unexposed. 
 
The novelty of our findings is several-fold. Our analysis is the first to control 
for other-cause mortality. Lack of accounting for mortality due to PCa or other-
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causes may artificially overestimate the effect of ADT on SREs. Cumulative 
incidence and competing-risks regression analyses control for the confounding 
effect of mortality. This is particularly important in elderly patients, as patients who 
die prematurely have no chance of experiencing the adverse outcome of interest 
i.e., one or several SREs.   
 
Elderly patients may also be affected by comorbidities. These may in turn 
lead to discontinuation of LHRHa. Such practice may also confound the true effect 
of ADT on SREs, as patients with multiple comorbidities may not be given an equal 
chance of being exposed to ADT and an equal chance of being diagnosed with one 
or several SREs. Our analysis controlled for comorbidities. 
 
Additionally, our analyses also controlled for other known confounders, such 
as age, anti-androgen exposure, postal code, region of residence, and year of 
treatment. Interestingly, although we considered exposure to anti-androgen, this 
variable failed to affect the rates of SREs. It could have been postulated that anti-
androgens might protect from SREs. 
 
Our study is not devoid of limitations. First, its design is not prospective. 
Therefore, the ascertainment of diagnoses may be subject to underreporting. Not 
all conditions might have been identified using diagnostic codes. However, it is 
unlikely that there are differences in the rate of reporting of diagnostic codes 
according to orchiectomy exposure status. Therefore, it is also unlikely that the 
relative measures of risk have been affected by differential misclassification bias. 
Similarly, the ascertainment of exposure (LHRHa vs. orchiectomy vs. no ADT) is 
unlikely biased, as LHRHa medication codes and orchiectomy reimbursement 
codes were used for exposure definition. It is unlikely that reimbursement would 
not be sought in orchiectomized patients or that dispensed LHRHa injections would 
not be used. 
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Universal access to health care represents a weakness, as well as an 
advantage of the current design. Access to orchiectomy in the Province of Quebec 
is not dictated by health insurance status. Nonetheless, the socioeconomic status 
(education) and temporal trends may have affected the rate of orchiectomy use 42. 
In consequence, we adjusted for both variables. The adjustment for year of 
treatment likely decreased or eliminated the confounding effect of temporal trends. 
However, adjustment for socioeconomic status by proxy of region of residence and 
postal code may not have completely eliminated the effect of socioeconomic 
status. Moreover, our analyses were limited by lack of consideration of several 
pharmacological agents aimed at SRE prevention, such as calcium, vitamin D or 
bisphosphonates. 
 
Finally, the administrative nature of our database precluded the 
consideration of disease stage. In consequence, it cannot be entirely excluded that 
orchiectomy patients by virtue of more advanced disease stage are not 
predisposed to higher rates of myocardial infarction and/or dementia. However, 
there is no evidence for such association and there is no biologic rationale for its 
existence.  
 
Despite these limitations, our findings provide valuable information about 
potential detriments of ADT exposure. They should be used in treatment decision-
making when ADT exposure is considered.          
 
  
Conclusion 
In conclusion, exposure to prolonged LHRHa therapy significantly increases 
the incidence rates of osteoporosis, spinal and hip fractures in Canadian men. 
Moreover, of twelve morbidities, exposure to prolonged LHRHa therapy increases 
the incidence rates of only three of them, namely: dementia, peripheral vascular 
disease and cerebrovascular disease. These findings confirm the detrimental effect 
of LHRHa on fracture rates in men from outside of the US. These results also 
confirm the effect of ADT on cardiovascular risks and cognitive function. Although 
the effect is weak, it still warrants caution in the setting of pre-existing morbidities 
when ADT is considered. Orchiectomy is associated with higher incidence rates of 
osteoporosis, spinal and hip fractures. Preventive or therapeutic measures should 
be considered if this treatment modality is chosen. However, of twelve morbidities, 
orchiectomy was associated only with higher incidence rates of dementia. 
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